EurekAlert!

PBPK model precisely predicts drug–drug interactions between prodrug GP681 and CYP3A4 inhibitors, offering new guidance for safe influenza therapy

Suraxavir marboxil (GP681) is an orally available prodrug that is converted in vivo to the active metabolite GP1707D07, a PA-targeting antiviral against influenza. Because GP1707D07 is primarily ...
Science Daily

Study provides scaffold to selectively target drug breakdown process

Scientists explored selectively blocking the CYP3A4 protein responsible for breaking down large swaths of approved drugs, providing a way to improve drug efficacy. Scientists at St. Jude Children's ...
BioWorld

Texas A&M University System divulges new SARS-CoV-2 3CLpro and CYP3A4 inhibitors

Texas A&M University System has discovered 3C-like proteinase (3CLpro) (SARS-CoV-2; COVID-19 virus) and cytochrome P450 3A4 (CYP3A4) inhibitors reported to be useful for the treatment of SARS-CoV-2 ...
Medscape

Update on the Pharmacogenomics of Proton Pump Inhibitors

Omeprazole, the prototype drug of PPIs, is metabolized primarily by CYP2C19 to 5-hydroxyomeprazole. 5-hydroxyomeprazole is then transformed into 5-hydroxyomeprazole sulfone by CYP3A4. Omeprazole is ...